J Capital Research

Independent Insight Provider

J Capital Research, a U.S. company, publishes highly diligenced research reports on publicly traded companies, relying on deep, on-the-ground primary research. J Capital has particular expertise in the Chinese market, but we look at over-valued companies throughout the world. As an activist short- and long-research shop, when we form a clear view, we publish free, public reports to inform the investing public and never disguise our identity. We believe the internet has afforded an opportunity to small, unaffiliated investors to leapfrog the big banks, with their conflicts of interest, and obtain unbiased information on traded companies. We pride ourselves on our independence and the quality of our work. We hope the work speaks for itself.

Thematic (Sector/Industry)

<ul><li>This week, we review the troubled history of Gryphon Digital Mining (GRYP), the reverse-merger partner of Hut 8’s (HUT) new spin-off, American Bitcoin, soon to trade on Nasdaq as ABTC.</li><li>HUT will own 80% of the spin-off. GRYP is the junior partner in the deal; its shareholders get 2% of the spin-off.</li><li>But there is magic somewhere in the numbers: based on GRYP's own current market cap, the 2% allocation implies a valuation for American Bitcoin that is more than twice the current market cap for all of HUT—even though most of its ABTC's operations are still currently contained in HUT as a majority owned subsidiary.</li></ul>

This week, we review the troubled history of Gryphon Digital Mining (GRYP), the reverse-merger partner of Hut 8’s (HUT) new spin-off, American Bitcoin, soon to trade on Nasdaq as ABTC.HUT will own 80% of the spin-off. GRYP is the junior partner in the deal; its shareholders get 2% of the spin-off.But there is magic somewhere in the numbers: based on GRYP's own current market cap, the 2% allocation implies a valuation for American Bitcoin that is more than twice the current market cap for all of HUT—even though most of its ABTC's operations are still currently contained in HUT as a majority owned subsidiary.

United States

Semler Scientific, Inc. operates as a medical risk-assessment company. The Company develops, manufactures, and markets diagnostic and testing products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler Scientific market its products in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00